Effects of l-Arginine Plus Vitamin C Supplementation on Physical Performance, Endothelial Function, and Persistent Fatigue in Adults with Long COVID: A Single-Blind Randomized Controlled Trial

The intervention was a combination supplement containing 1.66 grams of l-arginine plus 500 milligrams of liposomal vitamin C, taken twice daily (total daily dose: 3.32 g l-arginine + 1,000 mg vitamin C). The comparator was an identical-looking placebo (no active ingredients), also taken twice daily. Both groups took their assigned treatment for 28 consecutive days.

The researchers measured four main outcomes:

**Primary outcome:** Distance walked in 6 minutes (6-minute walk test, or 6MWT) — a standard measure of functional exercise capacity.

**Secondary outcomes:** Handgrip strength (a measure of overall muscle strength), flow-mediated dilation (FMD — a non-invasive ultrasound measure of how well the inner lining of blood vessels, the endothelium, can dilate in response to increased blood flow), and self-reported persistence of fatigue (whether participants still felt fatigued at the end of the study).

The rationale was that l-arginine is a precursor to nitric oxide (NO), a molecule that relaxes blood vessels and improves blood flow. Vitamin C was added because it protects NO from oxidative degradation and may enhance its production. Long COVID is associated with endothelial dysfunction (stiff, poorly responsive blood vessels) and reduced NO availability, so boosting NO production could theoretically improve both blood flow and muscle function.

Fifty participants were recruited from a post-acute COVID-19 outpatient clinic in Italy. All had confirmed prior SARS-CoV-2 infection (by PCR or serology) and reported persistent fatigue lasting at least 4 weeks after recovery from the acute phase. Inclusion criteria were: age 20–60 years, no current hospitalization, no severe organ failure, and no contraindications to the supplement (e.g., known allergy, recent herpes outbreak, or use of medications that interact with l-arginine such as nitrates or sildenafil).

Forty-six participants completed the study (23 per group). Their median age was 51 years (interquartile range 14 years, meaning half were between roughly 44 and 58). Sixty-five percent were women. The median time since COVID-19 diagnosis was not explicitly reported, but all had "persistent fatigue" and were attending a post-COVID clinic, suggesting they were several weeks to months post-infection. Participants were excluded if they had used any dietary supplements in the 30 days prior to enrollment.

This is a relatively small, homogeneous sample — all Italian, mostly middle-aged, mostly women, all with persistent fatigue severe enough to seek outpatient care. Results may not generalize to younger adults, men, asymptomatic long COVID, or different ethnicities.

**6-minute walk test (6MWT):** Participants walked as far as possible on a flat, 30-meter corridor for 6 minutes. The distance covered was recorded in meters. This is a well-validated test of submaximal exercise capacity used in heart failure, COPD, and now long COVID. It reflects the integrated response of the cardiovascular, respiratory, and muscular systems.

**Handgrip strength:** Measured using a hand dynamometer (Jamar, a standard device). Participants squeezed as hard as possible with their dominant hand, and the best of three attempts was recorded in kilograms. This is a proxy for overall muscle strength and correlates with frailty and functional status.

**Flow-mediated dilation (FMD):** A non-invasive ultrasound technique. A blood pressure cuff was inflated on the forearm for 5 minutes to occlude blood flow, then released. The diameter of the brachial artery (in the upper arm) was measured before and after cuff release. FMD is calculated as the percentage increase in artery diameter from baseline. Normal values in healthy adults are typically 6–10%; values below 5% indicate endothelial dysfunction. This is a gold-standard measure of endothelial health.

**Fatigue persistence:** A simple binary question: "Do you still feel fatigued?" answered yes or no at the end of the 28-day period. This is a crude measure — it does not capture severity, frequency, or type of fatigue (e.g., physical vs. mental). The authors also used a visual analog scale (VAS) for fatigue severity (0–10), but the primary fatigue outcome was the binary persistence question.

**Study design:** This was a single-blind, randomized, placebo-controlled trial. "Single-blind" means the participants did not know whether they were receiving the active supplement or placebo, but the researchers and outcome assessors did know. This is a significant weakness — ideally, both participants and assessors should be blinded (double-blind) to prevent bias in how outcomes are measured or interpreted. The authors state that the supplement and placebo were "identical in appearance, taste, and packaging," so participant blinding was likely adequate, but the lack of assessor blinding means that the person administering the 6MWT or measuring FMD could unconsciously influence results.

**Randomization:** Participants were randomized 1:1 to active or placebo using a computer-generated random sequence. The allocation was concealed (the sequence was kept in sealed opaque envelopes), which prevents selection bias. However, the small sample size (50 total) means that random imbalance in baseline characteristics is possible. The authors report that baseline age, sex, BMI, and 6MWT distance were similar between groups, which is reassuring but not definitive.

**Duration:** The intervention lasted 28 days. This is relatively short for a nutritional intervention — l-arginine's effects on NO production can occur within hours to days, but sustained improvements in muscle function and walking capacity may take longer to manifest. The 28-day window is reasonable for a pilot trial but does not tell us whether effects persist after stopping supplementation, or whether longer treatment yields greater benefits.

**Statistical approach:** The primary analysis was intention-to-treat (all randomized participants included, regardless of adherence). However, 4 participants dropped out (2 in each group) and were excluded from the final analysis, making this a per-protocol analysis. The authors used non-parametric tests (Mann-Whitney U test) for continuous outcomes because the data were not normally distributed. For the binary fatigue outcome, they used Fisher's exact test. They did not adjust for multiple comparisons (testing 4 outcomes increases the risk of false positives). The p-values reported are two-sided, with significance set at p < 0.05.

**What this design can and cannot prove:**

**Can prove:** That the supplement caused the observed improvements in walking distance, grip strength, FMD, and fatigue, compared to placebo, in this specific population over 28 days. Randomization controls for confounding (e.g., differences in diet, activity, or disease severity), and the placebo control accounts for the expectation effect.

**Cannot prove:** Long-term safety or efficacy beyond 28 days. Whether effects persist after stopping. Whether the supplement works in other populations (e.g., younger adults, men, those without fatigue). Whether l-arginine alone or vitamin C alone would work — the combination was tested as a single intervention. Whether the effects are clinically meaningful (a 30-meter improvement on the 6MWT is modest — about 5–10% of normal walking distance). Whether the supplement prevents or treats other long COVID symptoms (e.g., brain fog, chest pain, palpitations).

**Major methodological weaknesses:**

1. **Single-blind design** — assessor bias is possible, especially for subjective measures like the 6MWT (where encouragement can influence performance) and FMD (where image analysis requires judgment).

2. **Small sample size** — 23 per group limits statistical power and increases the risk of false positives or inflated effect sizes.

3. **Short duration** — 28 days is not long enough to assess sustainability or long-term adverse effects.

4. **Crude fatigue measure** — a binary yes/no question is insensitive to changes in fatigue severity or quality.

5. **No adjustment for multiple comparisons** — with 4 outcomes, the chance of at least one false positive is ~19% (1 – 0.95^4).

6. **No washout or follow-up** — we don't know if effects reverse after stopping.

7. **Industry funding not disclosed** — the authors report no conflicts, but the supplement manufacturer may have provided product or funding (not stated).

All results are reported as median (interquartile range) unless otherwise noted. The p-values compare the active group to the placebo group at 28 days.

**Primary outcome:**

**6-minute walk distance:** Active group improved from baseline by +30 meters (IQR 40.5 m). Placebo group improved by +0 meters (IQR 75 m). The difference between groups was statistically significant (p = 0.001). In plain terms, the active group walked 30 meters farther after 28 days, while the placebo group showed no change on average.

**Secondary outcomes:**

**Handgrip strength:** Active group improved by +3.4 kg (IQR 7.5 kg). Placebo group improved by +1.0 kg (IQR 6.6 kg). The difference was significant (p = 0.03). This is a modest but real increase — roughly equivalent to gaining 5–10% of baseline grip strength.

**Flow-mediated dilation (FMD):** At 28 days, the active group had a median FMD of 14.3% (IQR 7.3%), compared to 9.4% (IQR 5.8%) in the placebo group (p = 0.03). Both groups improved from baseline (which was not reported numerically), but the active group improved more. An FMD of 14.3% is considered normal to excellent; 9.4% is borderline normal.

**Fatigue persistence:** At 28 days, only 2 of 23 participants in the active group (8.7%) still reported feeling fatigued, compared to 21 of 23 in the placebo group (80.1%). This difference was highly significant (p < 0.0001). This is a dramatic effect — a 71-percentage-point reduction in fatigue prevalence.

**Adverse events:** The authors report no serious adverse events. Mild gastrointestinal discomfort (bloating, nausea) occurred in 3 participants in the active group and 1 in the placebo group. No participants withdrew due to side effects.

Let's translate these numbers into everyday terms:

**Walking distance:** A 30-meter improvement on the 6MWT is roughly equivalent to 30–40 extra steps, or about 5–10% of the normal walking distance for a healthy 50-year-old (typically 500–600 meters in 6 minutes). For context, a typical city block is about 100 meters. So this improvement is like being able to walk an extra third of a block in 6 minutes. It's a modest but real functional gain — enough to notice when walking to the mailbox or around the grocery store, but not a life-transforming change.

**Handgrip strength:** A 3.4 kg improvement is roughly equivalent to the strength difference between a 50-year-old and a 40-year-old (grip strength declines about 1 kg per decade after age 30). It's about the weight of a large bag of sugar or a small dumbbell. This is a meaningful increase for daily activities like carrying groceries, opening jars, or lifting children.

**Flow-mediated dilation:** An increase from ~9% to ~14% is a substantial improvement in endothelial function. For comparison, a single session of aerobic exercise typically improves FMD by 2–3 percentage points. A 5-percentage-point improvement is roughly equivalent to what you'd see after 8–12 weeks of regular exercise training or after starting a statin medication. This suggests the supplement is having a real physiological effect on blood vessel health.

**Fatigue:** The reduction from 80% to 9% reporting fatigue is enormous. However, this is a binary measure — it doesn't tell us about fatigue severity or quality. It's possible that some participants in the active group still felt somewhat tired but not enough to say "yes" to the question. The placebo group's 80% fatigue rate at 28 days suggests that long COVID fatigue does not resolve quickly on its own. If this finding is real, it means the supplement eliminated fatigue in 9 out of 10 people who took it — a remarkably large effect that warrants cautious interpretation given the small sample and crude measurement.

**Acknowledged by authors:**

Small sample size (46 completers)

Single-blind design (participants blinded, but not assessors)

Short intervention period (28 days)

Lack of long-term follow-up

No measurement of l-arginine or NO levels in blood to confirm absorption or mechanism

Single-center study in Italy, limiting generalizability

**Additional critical observations:**

**No intention-to-treat analysis:** The 4 dropouts were excluded, which can bias results if dropouts differed between groups (e.g., if those who felt worse dropped out of the placebo group, the remaining placebo group would look healthier).

**Crude fatigue measurement:** A single yes/no question is highly susceptible to expectation bias. Participants who guessed they were on the active supplement (because of taste, energy changes, or side effects) might be more likely to report fatigue resolution. A validated fatigue scale (e.g., Fatigue Severity Scale, Chalder Fatigue Questionnaire) would have been more robust.

**No adjustment for multiple comparisons:** With 4 outcomes tested, the p-values should be interpreted cautiously. The fatigue result (p < 0.0001) is robust enough to survive correction, but the grip strength and FMD results (p = 0.03) might not.

**Combination product:** We cannot tell whether l-arginine alone, vitamin C alone, or the combination is responsible for the effects. Vitamin C is a known antioxidant and NO protector, but it's also possible that the liposomal formulation improved absorption of both compounds.

**Baseline FMD not reported:** The authors report FMD at 28 days but not at baseline, so we cannot calculate the change within groups. This makes it harder to assess whether the active group started with better endothelial function.

**No control for lifestyle factors:** Participants were not instructed to change diet, exercise, or sleep habits. If the active group coincidentally increased physical activity (because they felt better), that could confound the results.

**Potential for publication bias:** Small positive trials are more likely to be published than small null trials. This study should be replicated before strong conclusions are drawn.

For someone running their own n=1 experiment to test whether l-arginine plus vitamin C improves their post-viral fatigue or physical performance:

**What to test:**

**Intervention:** l-Arginine 1.66 g (1,660 mg) plus liposomal vitamin C 500 mg, taken twice daily (morning and evening) with food. Total daily dose: 3.32 g l-arginine + 1,000 mg vitamin C. Use a combined product or take separately. Liposomal vitamin C is preferred for better absorption, but standard vitamin C may also work (though at lower bioavailability).

**Dosage form:** Capsules or powder. l-Arginine powder has a bitter, salty taste; capsules are easier to tolerate. Start with half the dose for 3 days to check for gastrointestinal side effects (bloating, diarrhea, nausea).

**Minimum meaningful duration:**

Run the experiment for **28 days** (matching the study). Effects on fatigue may appear within 1–2 weeks, but walking distance and grip strength improvements likely require the full 4 weeks. If you stop earlier, you may miss the effect.

Consider a **2-week baseline period** before starting the supplement to measure your normal performance and fatigue levels. Then 28 days on supplement, followed by a 2-week washout (no supplement) to see if effects reverse.

**What to